...
首页> 外文期刊>Kidney and blood pressure research >No Association of Angiotensin-Converting Enzyme Inhibitor or Angiotensin 2 Receptor Blocker Intake with Acute Kidney Injury in Patients Undergoing Kidney Biopsy
【24h】

No Association of Angiotensin-Converting Enzyme Inhibitor or Angiotensin 2 Receptor Blocker Intake with Acute Kidney Injury in Patients Undergoing Kidney Biopsy

机译:接受肾活检的患者中,血管紧张素转换酶抑制剂或血管紧张素2受体阻滞剂摄入与急性肾损伤无关联

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Background: Treatment with angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin 2 receptor blockers (ARBs) is associated with an increased risk for acute kidney injury after cardiovascular interventions. However, for patients undergoing kidney biopsy, no data is available. Methods: Four hundred and sixty-six patients undergoing kidney biopsy were retrospectively analyzed of whether or not concomitant intake of ACEIs or ARBs impairs kidney function. Results: Three hundred and twenty-three patients received ACEIs or ARBs or both before kidney biopsy. ACEI/ARB intake had no effect on kidney function compared to patients without this medication (all p > 0.05). Conclusion: Treatment with ACEIs or ARBs is not associated with risk of acute kidney injury in subjects undergoing kidney biopsy.
机译:背景:使用血管紧张素转换酶抑制剂(ACEIs)或血管紧张素2受体阻滞剂(ARBs)进行治疗与心血管介入术后急性肾损伤的风险增加有关。但是,对于正在进行肾活检的患者,没有可用数据。方法:回顾性分析了666例接受肾脏活检的患者是否同时摄入ACEIs或ARBs会损害肾脏功能。结果:233例患者在进行肾脏活检之前接受了ACEIs或ARBs或两者都接受。与不使用这种药物的患者相比,摄入ACEI / ARB对肾脏功能没有影响(所有p> 0.05)。结论:在接受肾活检的受试者中,ACEIs或ARBs治疗与急性肾损伤风险无关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号